BR112017006240A2 - novos compostos - Google Patents

novos compostos

Info

Publication number
BR112017006240A2
BR112017006240A2 BR112017006240A BR112017006240A BR112017006240A2 BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2 BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A BR112017006240 A BR 112017006240A BR 112017006240 A2 BR112017006240 A2 BR 112017006240A2
Authority
BR
Brazil
Prior art keywords
new compounds
pyrazole
salt
compound
formula
Prior art date
Application number
BR112017006240A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Hancock Ashley
Martin Pritchard John
Howard James Campbell-Crawford Matthew
Andrew Anderson Niall
Alexandrou Procopiou Panayiotis
Lemma Seble
John Fawcett Macdonald Simon
Swanson Stephen
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017006240A2 publication Critical patent/BR112017006240A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112017006240A 2014-09-26 2015-09-22 novos compostos BR112017006240A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1417018.7A GB201417018D0 (en) 2014-09-26 2014-09-26 Novel compounds
PCT/EP2015/071798 WO2016046241A1 (en) 2014-09-26 2015-09-22 Novel compounds

Publications (1)

Publication Number Publication Date
BR112017006240A2 true BR112017006240A2 (pt) 2017-12-12

Family

ID=51901174

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006240A BR112017006240A2 (pt) 2014-09-26 2015-09-22 novos compostos

Country Status (12)

Country Link
US (1) US10004724B2 (cg-RX-API-DMAC10.html)
EP (1) EP3197895B1 (cg-RX-API-DMAC10.html)
JP (1) JP6672276B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170054413A (cg-RX-API-DMAC10.html)
CN (1) CN107074850A (cg-RX-API-DMAC10.html)
AU (1) AU2015320874A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017006240A2 (cg-RX-API-DMAC10.html)
CA (1) CA2962319A1 (cg-RX-API-DMAC10.html)
ES (1) ES2796235T3 (cg-RX-API-DMAC10.html)
GB (1) GB201417018D0 (cg-RX-API-DMAC10.html)
RU (1) RU2017114352A (cg-RX-API-DMAC10.html)
WO (1) WO2016046241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
EP3538528B1 (en) 2016-11-08 2020-12-23 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
PT3538525T (pt) 2016-11-08 2022-08-16 Bristol Myers Squibb Co Ácidos propiónicos 3-substituídos por inibidores de alfa v integrina
CN110167934B (zh) 2016-11-08 2022-06-10 百时美施贵宝公司 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物
AU2017359028A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
EP4159727B1 (en) 2017-02-28 2026-04-08 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP7291696B2 (ja) 2017-11-07 2023-06-15 ブリストル-マイヤーズ スクイブ カンパニー アルファvインテグリン阻害剤としてのピロロピラジン誘導体
PT3844162T (pt) 2018-08-29 2025-03-28 Morphic Therapeutic Inc Inibidores da integrina alfa v beta6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
AU2019327475B2 (en) 2018-08-29 2025-06-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047425A4 (en) * 1997-12-17 2009-04-22 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
EP1229910A4 (en) 1999-10-04 2003-10-01 Merck & Co Inc integrin
YU32502A (sh) 1999-11-08 2004-12-31 Merck & Co.Inc. Postupak i intermedijeri za proizvodnju imidazolidinonskih antagonista alfa v integrina
JP2004511434A (ja) * 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
AU7793501A (en) 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
MX2009010050A (es) 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
AU2016228852A1 (en) 2015-03-10 2017-10-19 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
AU2015320874A1 (en) 2017-03-09
WO2016046241A1 (en) 2016-03-31
EP3197895A1 (en) 2017-08-02
GB201417018D0 (en) 2014-11-12
CN107074850A (zh) 2017-08-18
JP2017528506A (ja) 2017-09-28
US20170290818A1 (en) 2017-10-12
RU2017114352A (ru) 2018-10-26
JP6672276B2 (ja) 2020-03-25
ES2796235T3 (es) 2020-11-26
EP3197895B1 (en) 2020-03-11
CA2962319A1 (en) 2016-03-31
KR20170054413A (ko) 2017-05-17
US10004724B2 (en) 2018-06-26

Similar Documents

Publication Publication Date Title
BR112017006253A2 (pt) novos compostos
CO2018004124A2 (es) Compuestos heterocíclicos
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
MX377277B (es) Derivados de fenoximetilo.
TW201613911A (en) Heterocyclic compounds and uses thereof
BR112016028773A2 (pt) processos para preparação de compostos antivirais
BR112017006251A2 (pt) novos compostos
CR20160098A (es) Polimorfo de los inhibidores de la syk
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CO2017000332A2 (es) Coŵpuestos heterocíclicos como receptores huérfanos relacionados con retinoide gamma-t (ror γt)
JOP20170169A1 (ar) مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
MA40302A1 (fr) Dérivés de carbazole
CL2015002027A1 (es) Compuestos quimicos
MX380550B (es) Sintesis de indazoles.
EA201891278A1 (ru) Гетероциклические индолы для применения при инфекции, вызванной вирусом гриппа
EA201892449A1 (ru) Конденсированные гетероциклические соединения
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm
MX387796B (es) Compuestos de aminocarbonilcarbamato.
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
AU2015309863A8 (en) Azaindole derivative having AMPK-activating effect
BR112018008006A2 (pt) composto de piranodipiridina
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
MX379401B (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]